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EfﬁcacySexually transmitted infections like HIV, HPV, and HSV-2, as well as unplanned pregnancy, take a huge toll on
women worldwide. Woman-initiated multipurpose prevention technologies that contain antiviral/antibacterial
drugs (microbicides) and a contraceptive to simultaneously target sexually transmitted infections and unplanned
pregnancy are being developed to reduce these burdens. This reviewwill consider products that are applied top-
ically to the vagina. Rectally administered topical microbicides in development for receptive anal intercourse are
outside the scope of this review. Microbicide andmicrobicide/contraceptive candidates must be rigorously eval-
uated in preclinical models of safety and efﬁcacy to ensure that only candidates with favorable risk beneﬁt ratios
are advanced into human clinical trials. This reviewdescribes the comprehensive set of in vitro, ex vivo, and in vivo
models used to evaluate the preclinical safety and antiviral efﬁcacy ofmicrobicide andmicrobicide/contraceptive
candidates.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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The origins of sexually transmitted infections (STIs), also known as
venereal infections, may date back as far as the very beginning of
civilization. The etymology of the name venereal is related to the goddess
Venus, synonymous of love and fertility, perhaps to describe the need forthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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consequences of acquiring such infections are far from pleasant [1].
The etiological agents of STIs are bacteria, protozoans, viruses and chla-
mydias among which are: Neisseria gonorrhoeae, Treponema pallidum,
Trichomonas vaginalis, Chlamydia trachomatis, human immunodeﬁcien-
cy virus (HIV), herpes simplex virus 2 (HSV-2), human papillomavirus
(HPV) and hepatitis B virus (HBV).
According to the World Health Organization (WHO) estimates, 499
million curable STIs occur each year in the world [2]. This number
excludes pathogens like HIV, HSV-2 and HPV, the three sexually trans-
mitted viral infections with the greatest impact on human health. All
three viruses cause chronic or latent infections, which cannot be elimi-
nated through any antiviral treatment, resulting in high morbidity or
mortality. Additionally, infections by HSV-2 or HPV can increase the
risk of HIV infection [3,4]making novel strategies to prevent their trans-
mission a priority area of research to improve the welfare of millions of
human beings, most of them living in third world countries.
Vaccines are available for the prevention of HPV 6, 11, 16 and 18
types [5]. However, there are some limitations that may require
additional prevention tools for HPV infections. These limitations in-
clude the lack of protection against other HPV types associated
with anogenital infections (36 types), the need of cold chain distri-
bution and storage and low worldwide vaccine coverage, in part
due to a very high cost [6]. Changes in sexual behavior through
counseling, availability of condoms for men or women, the use of an-
tiretroviral (ARV) therapy in HIV infected persons in serodiscordant
couples, male circumcision and treatment of STIs can reduce the risk
of acquiring HIV or other STIs. But despite having all these tools, infec-
tions by sexually transmitted pathogens have stabilized or increased
in various parts of the world and new strategies are needed to ﬁght
STIs. A more recent idea proposes the use of microbicides, which are
novel topical products containing active pharmaceutical ingredients
(APIs) to block the infection by these pathogens. These APIs may be de-
livered intravaginally or intrarectally, using different delivery systems
including gels, creams, ﬁlms, suppositories, probiotics, nanoﬁbers or
intravaginal rings (IVRs). The vaginal formulations may also include
contraceptives, opening the ﬁeld of multipurpose prevention technolo-
gies (MPTs), to not only prevent HIV and/or other STIs but also unin-
tended pregnancy [7].
The novelty of this approach imposes a very cautious and rigorous
preclinical evaluation of safety and efﬁcacy in order to move forward
the most promising microbicides and microbicide/contraceptives into
clinical trials. These studies, mostly guided by prerequisites suggested
or imposed by regulatory agencies that approve studies in humans,
help to follow a rational and ethical approach that will ﬁnally allow
the start of clinical trials. This reviewwill focus on the preclinical assess-
ment of safety and efﬁcacy of vaginal microbicide and microbicide/
contraceptive candidates with particular emphasis on preclinical
models to evaluate efﬁcacy against HIV, HSV-2 and HPV, as well as
safety. It is important to emphasize the equal importance of development
of rectal microbicides to prevent these STIs also transmitted through
rectal intercourse. However, this review will focus on vaginal models
as part of this special issue devoted to vaginal drug delivery.
2. The female reproductive tract as a media for establishing HIV,
HSV-2 and HPV infections
The design of an effective vaginal microbicide requires under-
standing the steps that the viruses follow to establish infection in
the female genital tract (Fig. 1). Female genital mucosa consists of
stratiﬁed squamous epithelial tissue in the vagina and ectocervix,
while the endocervix is composed of columnar epithelium. The vaginal
mucus and intact vaginal epithelial tissues provide the ﬁrst barriers that
HIV must overcome before it can infect the host cells, the CD4+ T cells
[8]. However, the loss of tissue integrity as a result of ulcerative genital
infections (as caused by HSV-2, for example) or abrasions that occurduring intercourse or possibly transcytosis [9], can allow HIV to enter
epithelial tissues and establish productive infection in target cells. The
main cellular targets are CD4+ T lymphocytes, CD4+ cells of the
macrophage lineage and dendritic cells (DCs). DCs efﬁciently capture
HIV and transmit captured or newly produced virus to T cells [10],
where the DC–T cell communication drives robust virus replication
[11]. Interestingly, HSV-2 may modulate its microenvironment after
infecting DCs to drive HIV infection in the DC–T cell mixtures [12]
(Goode et al., in preparation). HIV starts its replication cycle by
interacting with receptors (CD4, α4β7) [13,14] and coreceptors
(CCR5, CXCR4) [15] on the surface of target cells. This process of adsorp-
tion and subsequent entry into the cells, followed by reverse transcrip-
tion and integration, are all targets being exploited to develop potential
microbicides that may block infection [16–38].
Epithelial cells are also the ﬁrst type of cells that HSV-2 and HPV
encounter, although unlike with HIV, epithelial cells constitute the
primary target and site of replication of these viral infections. HSV-2
has several viral glycoproteins in the virion surface that play an impor-
tant role in adsorption and entry to epithelial cells, which makes them
attractive targets to develop microbicidal compounds that could block
these steps [39]. The adsorption and entry are a complex process that in-
volves interactionwith heparan sulfate and other receptors like herpes-
virus entry mediator (HVEM) and nectin to then induce conformational
changes that result in fusion with the cell membrane [39]. The next
steps are translocation of the nucleocapsid to the nucleus, viral gene
expression and genome replication. Inhibition of viral enzymes that
participate in these steps, like the viral DNApolymerase, could help pre-
vent HSV-2 infection [39]. After replicating initially in epithelial cells,
HSV-2 is transported retrogradely along the axon of sensory neurons
to establish latency in the sensory ganglion. The latency is kept under
surveillance of the immune system that also controls the virus present
in themucosa [39]. Under certain conditions, including stress, immuno-
deﬁciency or immunosuppression, the virus is reactivated and taken
through anterograde transport back to the genital mucosa where once
again HSV-2 replicates [39]. During this replication, HSV-2 may or
may not cause lesions in epithelial tissues and be transmitted to another
susceptible host [39]. HPV limits its tropism to epithelial cells and re-
quires damaged epithelia, where the basement membrane is exposed,
to start the infection. The virus ﬁrst attaches to heparan sulfate on the
basement membrane and then undergoes a conformational change
followed by cleavage (perform by furin and/or PC5/6) of the structural
protein L2. The cleavage results in amodiﬁed virion that can now attach
to a secondary receptor in basal keratinocytes and enter these cells [40].
Although heparan sulfate has been suggested as the universal receptor
for attachment to the basement membrane, other studies have shown
that infection of human keratinocytes with tissue-derived HPV 31 does
not required heparan sulfate [41]. After entering basal keratinocytes the
virus continues through a complex cycle of replication that requires
cellular factors that are present at different stages of the epithelium
differentiation. During this process viral enzymes like DNA polymerase
may constitute interesting targets to prevent infection, but compounds
like cidofovir, known to inhibit this particular enzyme [42], may not
have a favorable enough toxicity proﬁle to warrant its use as a potential
microbicide [43].3. Selecting a microbicide candidate
The ﬁrst step in the development of microbicides is to identify APIs
that may block STIs. Candidates must have a good therapeutic index
(TI), inhibit virus replication at low, non-toxic concentrations in vitro,
have a good resistance proﬁle, be stable, and have the potential for
reasonable pricing. Fig. 2 shows a go/no-go chart that combines the
preclinical assessment of safety, efﬁcacy and quality of microbicide
candidates, highlighting in green boxes the steps that will be discussed
in the next sections.
Fig. 1.HIV, HSV-2 and HPV initial site of replication and possible strategies to prevent infection withmicrobicides. The three viruses share the same route of infection when sexually transmitted, but with differences in tropism and pathogenesis. The
















Fig. 2. Possible GO/NO-GO algorithm in microbicide product development. The green boxes are the topics described in this review.
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tant to microbicide development, stability, quality and acceptability
studies need to be incorporated early in the evaluation of a microbicide
candidate. These studies start by extensively evaluating thephysical and
chemical properties of the unformulated and formulated API, combina-
tions of APIs (when multiple APIs are present in the formulation), as
well as API compatibility with formulation excipients and chemical
stability. Additional tests and speciﬁcations on formulations include
pH, osmolality, rheological properties in the case of a gel, appearance,
odor, and content uniformity of drugs, impurities, dose volume, and
product dimensions [44].
Numerous classes of APIs have been tested as vaginal microbicides,
including virucidal agents (detergents [45]), molecules that block
virus adsorption and cell fusion (polyanions [45]), CCR5 co-receptor
antagonists [46,47], lectins [30,33,48] and neutralizing monoclonal
antibodies [49], nucleoside reverse transcriptase inhibitors (NRTIs) or
non-nucleoside reverse transcriptase inhibitors (NNRTIs) (Tenofovir
(TFV) [16,27], Dapivirine (DPV) [50], MIV-150 [25,28,29,34,36,51–53],
TDF [37,54] and UC781 [55]), and the viral integrase inhibitors
(L-870812, raltegravir) [56]. Table 1 summarizes the current state of
the art of vaginal microbicides and microbicide/contraceptives.4. In vitro safety and biological activity
4.1. Cytotoxicity and antiviral activity in cell-based assays
Many cell-based assays have been developed for the in vitro evalua-
tion of potential antiviral compounds. These assays yield the median
effective concentration (EC50), the average cytotoxic concentration
(CC50), and the therapeutic index (TI, or CC50/EC50). The EC90 (90%
inhibition) is also calculated to inform a rational dose selection
when formulating the potential microbicide and as an important
value to consider in pharmacokinetic (PK) and pharmacodynamic
(PD) studies. A minimum acceptable TI value typically ranges from 10
to 100. It is essential to have a cell line or primary cells in which the
virus replicates or at least mimics some of the target steps, and a meth-
od to quantify this replication like cytopathic effects, detection of viral
proteins or nucleic acids, reporter genes.
Fluorescent or colorimetric assays such as CyQuant, Vibrant
Assay, Presto Blue, Neutral Red, MTT and XTT are used to determine
the CC50 and EC50, offering great advantages in speed, simplicity and
cost [57]. Additionally, the use of differentiated monolayers to mea-
sure transepithelial electrical resistance (TEER), as a measure of
Table 1
State of the art of vaginal microbicide candidates.
Microbicide APIs Target Delivery system Study name Current
status
DPV HIV IVR Aspire Phase 3
The Ring Study Phase 3





DPV HIV Film, gel FAME-02 Phase 1
Completed
DPV, Maraviroc HIV IVR MTN-013 Phase 1
Completed
TFV HIV, HSV-2 Film, gel FAME-04 Phase 1
TDF HIV, HSV-2 IVR 2013-329 Phase 1
MIV-150, Zinc Acetate (ZA), Carrageenan (CG) HIV, HSV-2, HPV Gel Population Council
#558
Phase 1
TFV, IQP-0528 HIV IVR Preclinical Preclinical
MIV-150, ZA, CG, Levonorgestrel (LNG) HIV, HSV-2, HPV, unintended pregnancy IVR Preclinical Preclinical
TFV, LNG HIV, HSV-2, unintended pregnancy IVR CONRAD 128 Phase 1
TFV or Truvada HIV, HSV-2 Vaginal rapidly disintegrating tablets (RDTs) CONRAD 117 Phase 1
DPV, LNG HIV, unintended pregnancy IVR Preclinical Preclinical
Grifﬁthsin HIV, HSV-2, HPV Gel, IVR or nanoﬁber Preclinical Preclinical
Neutralizing Antibodies against HIV and HSV-2 HIV, HSV-2 Mapp 66 gel Preclinical Preclinical
a This study included a daily use of a tablet (TFV or Truvada) or daily use of a vaginal gel (1% TFV gel).
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29,35,58–60]. The assay is performed with differentiated vaginal,
ectocervical, endocervical or rectal epithelial monolayers. A modi-
ﬁed TEER assay, which measures TEER changes in the epithelial
monolayer after exposure to candidate microbicides followed by
challenge with HIV and measuring the ability of the virus to cross
the epithelium and infect target cells in the lower chamber, has
also been used [61]. Using this system, it was suggested that epithe-
lial barrier disruptionmight have contributed to the increased risk of
HIV acquisition observed in Phase 3 trials of N-9 and CS [61]. Addi-
tionally, in vitro permeability studies in a Franz cell model using ex-
cised ectocervical tissue have been described as a tool to determine
potential toxicity due systemic absorption and/or accumulation,
[62]. Another set of toxicity assays includes the assessment of meta-
bolic stability and potential interactions with CYP450 isoenzymes
[63]. Finally, genetic toxicology assays should be performed once a
lead API has been identiﬁed. Genetic toxicology includes assays
like the bacterial reverse mutation assay and in vitro chromosome
aberration assay in CHO cells with population doubling [63].
It is critical to minimize variables that may affect the in vitro evalua-
tion outcome so that objective comparisons can be performed between
laboratories and on different antiviral agents. These variables could be
the use of different laboratory virus strains or primary virus isolates in
different cell lines or primary cells, the use of different multiplicities of
infection (m.o.i., the number of infectious particles per cell) and the
antiviral assay per se.
In the speciﬁc case of HIV, the FDA recently issued guidance for the
preclinical evaluation of microbicides, which recommends the use of
certain assays in an attempt to standardize procedures and to be able to
compare results betweendifferent antimicrobial agents that are being de-
veloped [64]. The tests and criteria to consider include obtaining the
dose–response curves in peripheral blood mononuclear cells (PBMCs)
against a wide range of primary isolates (geographically and phenotypi-
cally different) but also include at least onewell-characterized laboratory
strain [29]; determining the antiviral activity in cervicovaginal and
colorectal explants [34,65] (Section 4.2); considering only those
agents with TI N 10; using an appropriate range of m.o.i.; determin-
ing antiviral activity against cell-free and cell-associated virus and
the possible interference of biological ﬂuids (semen and vaginal ﬂuid)
and pH transition in the antiviral activity of the potential microbicide
[66].A method traditionally used to test antiviral activity against lytic
viruses is the viral plaque assay, which despite being a laborious assay,
is reliable and reproducible. In the case of HSV-2, the plaque assay in
cell lines like Vero cells could be accepted as the “gold standard” for
determining the susceptibility to antiviral agents [57]. Other methods,
including dye-uptake assays, can be also employed to evaluate anti-
HSV-2 activity in vitro [57].
HPV relies on theprocess of epithelial differentiation to complete the
viral replication, starting in the basal keratinocytes and ﬁnishing with
the shedding of new viral progeny in the stratum corneum. In vitro
organotypic raft culture has been established to recreate this complex
process and allows the production of infectious virus to then infect pri-
mary human keratinocytes [41,67,68]. The system results in an efﬁcient
infection of primary human keratinocytes but the full virus life cycle can
be only achieved at very highm.o.i. Alternatively, a cell line-based assay,
using different types of HPV pseudovirus (PsV) has been described [69].
The testing of different HPV PsV types is essential to corroborate a
broad-spectrum anti-HPV activity. The assay can be performed using
ﬂow cytometry or luminescence in microplate formats [29,69,70]. It re-
lies on the self-assembly of the structural HPV proteins L1 or L1/L2,
which can encapsulate a reporter genome and mimic the early steps
of viral adsorption and entry into the epithelial cells. An important lim-
itation of this particular assay is that only compounds that target these
early steps in the HPV cycle of replication can be identiﬁed and tested.
Additionally, different susceptibility of primary human keratinocytes
to HPV (produced in organotypic raft culture versusHPV PsVs produced
in cell lines like 293 T cells) needs further investigation [41].
4.2. Toxicity and antiviral activity in explant models
The evaluation of microbicide candidates in explant models is per-
formed later in the preclinical evaluation timeline, typically after a
lead API/formulation has been identiﬁed. Explants represent biological-
ly relevant systems with STI target cells present in the context of the
correct environment and architecture [65]. Several explants models
have been described: (i) agarose or matrigel sealed polarized tissue
challenge/culture (HIV infection) [71,72]; (ii) tissue challenge by direct
application of viruses on the explant or immersion in virus/culture
media and subsequent culture on gel-foam rafts (HIV, HSV-2) [73];
(iii) non-polarized tissue challenge/culture (HIV, SHIV-RT, HSV-2) [17,
74–76].
32 J.A. Fernández-Romero et al. / Advanced Drug Delivery Reviews 92 (2015) 27–38The polarized explant cultures are used to assess product safety
(histopathological examination, MTT assay) [18,24,72]. API permeabili-
ty through tissues can be measured using a Franz diffusion cell [35].
Microbicide activity testing has been reported in both polarized and
non-polarized culture models. Several HIV and HSV-2 explant infection
models have demonstrated the anti-HIV activity of entry inhibitors,
NRTI, and NNRTIs, as well as the anti-HSV-2 activity of TFV [17,18,20,
24,26,35,72,77–79]. The advantage of antiviral activity testing in the
non-polarized model is that it allows assessment of multiple replicates
using readily obtained tissue samples, as the model typically uses 2–
3 mm blocks of tissue per assessment [74]. The tissues are incubated
with APIs or appropriately diluted formulated products (e.g., gel).
While tissue supply can be limiting, thismodel allows for the calculation
of EC50 and EC90 values for theAPIs and the analysis of the effects of drug
combinations [26,77]. In addition, the impact of a product on virus
transmission by cells that migrate from the mucosal tissues can also
be determined using this model [20,26,77,80]. In the polarized tissue
model larger tissue blocks are used and undiluted/minimally diluted
products are applied only on the epithelial surface of the tissue, which
mimics the in vivo scenario [72]. Furthermore, polarized tissue cultures
were recently utilized tomimic systemic exposure to the product, when
API was added in contact with explant basolaterally [35].
HIV efﬁcacy models in non-human primates use chimeric virus pre-
pared from the simian immunodeﬁciency virus (SIV) and genetic infor-
mation of HIV. The HIV genetic information incorporated in the SIV
genome is selected to match the mode of action of the antiretroviral
drug being tested. For example, when the compound blocks HIV reverse
transcription, a chimeric virus carrying the HIV RT is used. We recently
established models of cell-free and cell-associated SHIV-RT infection in
rhesus macaque vaginal and cervical explants [17,18,34] (Barnable
et al., in preparation). The Population Council's lead microbicide gel
containing the NNRTI MIV-150 and zinc acetate in carrageenan (MZC)
signiﬁcantly inhibited cell-free and cell-associated SHIV-RT infection
in tissues [18] (Barnable et al., in preparation). HIV/HSV-2 co-infection
models of human cervical mucosa [79] (Villegas et al., in preparation)
and SHIV-RT/HSV-2 co-infection of macaque vaginal mucosa (Calenda
et al., in preparation) also have been established and used for microbi-
cide activity testing. MZC provided anti-HIV, anti-SHIV-RT and anti-
HSV-2 activity in these models (Villegas et al., in preparation; CalendaTable 2
Advantages and disadvantages of in vitro and ex vivomodels to test safety and efﬁcacy of pote
Advantages
Cell-based assays
Safety • First-line safety screen.
• Cells of human origin.
• Fast and inexpensive.
Anti-HIV activity • EC50, EC90, TI calculation.
• Testing in the presence of biological ﬂuids.
• Fast, inexpensive in the case of assays performed in cell l
• Antiviral activity in primary cells (PBMCs) allows the test
a broad range of virus isolates, clones or lab adapted strai
Anti-HSV-2 activity • Plaque reduction assay is considered a “gold standard” fo
anti-HSV testing.
• EC50, EC90, TI calculation.
• Dye-uptake assays are fast and inexpensive.
Anti-HPV activity • EC50, EC90, TI calculation.
• Full cycle of HPV replication in keratinocytes or adsorptio
with PsVs in cell lines.
Tissue Explants (human, macaques)
Safety • Relevant HIV target cells/architectural context.
Anti-HIV and anti-HSV-2
activities
• Relevant HIV target cells/architectural context.
• Choice of polarized or non-polarized viral challenge and c
• EC50/EC90 calculation (surgical tissue, non-polarized mod
• Allows for assessing effect on HIV transmission by migrat
• Testing in the presence of seminal plasma.et al., in preparation). Antiviral activity of the products in explants is
measured by ELISA, PCR assays on supernatants, and PCR assays on tis-
sues and immunohistochemistry [72,74] (Villegas et al., in preparation;
Calenda et al., in preparation).
Overall, API/product testing in explants provides important informa-
tion that cannot be acquired with any other models. The system has
been used to test antiviral activity of APIs in the presence of biological
ﬂuids like vaginal ﬂuid and seminal plasma [17,18,34] (Villegas et al.,
in preparation; Calenda et al., in preparation). Additionally, safety and
antiviral activity in explants demonstrated some predictability of
results in the clinic [65]. However, there are several disadvantages of
the explant models: inability of the tissue to regenerate/repair, lack of
dynamic cell exchange, and the lack of hormonal control [81]. More-
over, the explant assays are cumbersome and costly. Table 2 summa-
rizes the advantages and disadvantages of in vitro and ex vivo assays
tomeasure safety and efﬁcacy (HIV, HSV-2 andHPV) of potentialmicro-
bicide formulations.
4.3. In vitro toxicity on normal microﬂora
In vitro assays to assess the impact of microbicide candidates on
bacterial ﬂora in the vagina should be performed in the early stage
of microbicide development [29,35,58,66,82]. This involves incubat-
ing various lactobacilli with the microbicide. Candidates that perturb
the bacterial balance in the vagina should be either reformulated or
discarded.
5. Selection and characterization of resistant viruses
This topic is especially relevant in the case of microbicides targeting
HIV. Antiviral resistance is deﬁned as a reduction of viral susceptibility
to an antiviral agent. A moderate resistance is when the EC50 value
increases from 5 to 10 fold while more than 10 fold increase results in
highly resistant viruses. This result may be conﬁrmed through genetic
analysis of the virus and the biochemical study of altered viral protein.
HIV persists in the host as viral quasispecies where the predominant
viral sequence is constantly changing as a selective pressure (especially
during ARV treatment) is exerted on the virus. This facilitates, under
certain circumstances, a rapid selection of resistant virus and treatmentntial microbicide formulations.
Disadvantages
• Single cell-type models
• Innate mediators: may be difﬁcult to interpret due to variability and




• Not all viruses, especially primary isolates, replicate well in assays
performed in cell lines.
• PBMC assay: donor-to-donor variation, not user-friendly and long
time to generate an end point.
r • Plaque reduction assay is tedious and consume more reagents,
appropriate for small-scale testing.
• Precipitation in dye-uptake assays may interfere with the results.
n/entry
• Producing virus stocks is laborious and expensive.
• Requires high m.o.i. to achieve full life cycle (keratinocytes).
• Only early steps of HPV replication cycle can be assessed
with PsVs in cell lines.
• Potentially different susceptibility to HPV in primary
cells vs. cell lines.
• No tissue regeneration/repair.
• No systemic effects (e.g., cell migration, hormonal inﬂuence).
• Survival cervical/vaginal biopsies are limiting in size.
• Cumbersome to obtain.
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minimize viral resistance is to combine several drugs with different
mechanisms of action, as it would require multiple mutations in the
same viral genome for the virus to acquire resistance. This antiviral
combination therapy is known as highly active ARV therapy (HAART).
However, if treatment is not strictly followed and/or there is lack of
monitoring, multidrug resistant viruses can arise [83].
In an ideal scenario, microbicides would be used by HIV-negative in-
dividuals to prevent infection. However, individuals who may or may
not know their HIV-positive status may use a microbicide or infected
people may choose to use a microbicide/contraceptive to avoid becom-
ing pregnant. This could start the selection of mutant viruses with re-
duced susceptibility to the antiretroviral drug. It is not clear whether
the topical, non-systemic use of ARVs is able to exert the necessary pres-
sure to select viral resistance. It is worth noting that many of the poten-
tial microbicides are not efﬁciently absorbed after vaginal application,
which may lead to very low concentrations of the APIs in the blood
stream [28,29,32,36,84,85]. Yet the viral population in the genitalmuco-
sa of infected individualsmay be prone to select resistant virus since API
levels might be higher there than in the systemic circulation. Recent
studies in macaques showed that while intramuscular administration
of the NNRTI MIV-150 results in selection of NNRTI-associated muta-
tions in SHIV-RT infected macaques, topical exposure of infected ani-
mals to MIV-150-containing IVRs resulted in limited emergence of
NNRTI-associated mutations [52] (Kenney et al. submitted).
In vitro selection of resistant viruses against the microbicide candi-
date is performed during preclinical development. The assay can be
run in cell lines or PBMCs using different susceptible HIV clades [19,
52,86]. The selected viruses must be characterized genetically and
phenotypically and cross-resistance with APIs used for HIV treatment
should be assessed. Selection of resistant viruses would help to predict
a possible reduction in the susceptibility of the virus to the microbicide
and/or other products (especially those being used in the treatment of
HIV infection) and indicate mutations that should be monitored in
clinical trials. Similarly, these experiments allow mechanism of action
studies on the microbicides since mutations in the target viral proteins
may help to better understand the API's mode of action.
6. In vivo exploratory studies
6.1. In vivo safety studies
Preclinical safety evaluation of microbicides starts with in vitro
assays that measure cytotoxicity in cell cultures or cervicovaginal and
colorectal tissue explants. However, these in vitro systems do not
allow a prolonged or repeated exposure to a microbicide candidate
and do not assess inﬂammatory responses that can only be seen in in-
tact mucosal tissues.
A series of in vivo models have been described in the literature to
assess preclinical safety in exploratory studies but require further
validation in order to standardize preclinicalmodels. Themucosal deliv-
ery of vaginal microbicides demands a close look at the integrity of
cervicovaginal mucosa and the possible development of inﬂammatory
processes after microbicide application. Breaks in the integrity of the
mucosa and inﬂammatory conditions will create an ideal environment
for the establishment of STIs.
Murine models include the increased susceptibility to infection by
HSV-2 in mice (Mus musculus), which could be used as a biomarker to
predict increased risk forHIV infection [29,58,60,87]. Themodel consists
on successive vaginal applications of a product (often a gel), before in-
fecting the mice with a suboptimal dose of HSV-2. If damage occurs
and impairs the integrity of the mice vaginal mucosa increased HSV-2
infection can be observed. Another model incorporates monitoring the
tight junctions in the epithelium, transcription factors in nuclear
extracts from vaginal tissues, and cytokine and chemokine analyses in
vaginal washes [88]. Histological analysis can also be performedin cervicovaginal tissues after vaginal application of microbicide
candidates in mice. This model looks into the architecture of the
cervicovaginal tissues and the presence of inﬂammatory inﬁltrates
within the lamina propria [29,58,60,89]. These murine models have
contributed to understanding the failure of some microbicide candi-
dates to show efﬁcacy by suggesting increased susceptibility to HSV-2
probably due to alterations in epithelial architecture [90].
Non-humanprimatemodels are also informative, where vaginal gels
can be repeatedly applied or IVRs inserted for extended periods of time
in pigtailed (Macaca nemestrina) or rhesusmacaques (Macaca mulatta).
These models monitor changes in pH, microﬂora, inﬂammatory inﬁl-
trates on tissues, cytokine and chemokine levels in vaginal swabs, mea-
suring the overall health of the vaginal mucosa [53,91–93] (Kenney
et al. submitted).
6.2. PK/PD of microbicide formulations
PK and PD studies can investigate the whole process of a drug from
the time it is applied intravaginally until elimination or removal. They
also give information on the biochemical and physiological effects, the
mechanism of action and the relationship between drug concentration
and effectiveness. The ideal microbicide should be distributed in tissues
susceptible to STIs, must be metabolized (if necessary) efﬁciently in
these tissues and achieve adequate and sustained concentrations at
the necessary sites. Additionally, as discussed earlier, avoiding systemic
circulation may minimize the development of viral resistance and/or
toxic effects.
Performing PK and PD studies of potential microbicides in animal
models has some notable challenges. The interpretation of the results
in animal models and the correlation to humans are complicated due
to physiological and biological differences. Additionally, we still need
to understand better the relevance of an API's presence in speciﬁc com-
partments or subcompartments. Most PK and PD preclinical studies of
microbicides have been carried out using macaque, murine, rabbit,
and sheep models. These studies have compared different doses after
single or repeated application of a microbicide formulation or after
using sustained release device, monitoring levels in vaginal ﬂuids, cervi-
cal and vaginal biopsies, as well as in plasma [21,27–29,31,32,34,36,37,
53,70,94,95]. In general, there is a need to improve and standardize PK
and PD animal models in the microbicide ﬁeld, especially the delinea-
tion of PK relationships between different animal models and between
human and animal models [96].
There is a signiﬁcant amount of data regarding TFV and Truvada
(tenofovir disoproxyl fumarate/emtricitabine) PK in animal and
human models after oral administration [97]. However, changing the
route to topical administration, like the case of vaginal microbicides, re-
quires a newanalysis of the PK and PD of the novel formulations. Several
studies have been performed in macaques or rabbits with TFV or with
Truvada. Vaginal gels or vaginal rapidly disintegrating tablets contain-
ing TFV alone or Truvada have produced sustained and biologically rel-
evant vaginal tissue levels of APIs that persisted up to 24 h after
administration in pigtailed macaques [94,95]. Similar results were also
achieved in PK studies performed in rhesus macaques and rabbits [21,
31]. PK studies inmacaques and rabbits have also informed the presence
of biologically relevant DPV concentrations in vaginal and cervical
tissues for more than 24 h after a single gel application [32]. Similarly,
PK studies in macaques with MZC gel, containing another NNRTI
(MIV-150) but at a lower dose, have shown biologically relevant MIV-
150 concentrations for more than 8 h [28,29]. This observation parallels
the full protection seen after application of the MZC gel 8 h before
vaginal SHIV-RT challenge in macaques [28]. Interestingly, novel PD
preclinical models are suggesting the need of sustained released of
some microbicide candidates like NNRTIs [98]. In fact, a DPV IVR is cur-
rently in Phase 3 trial, and PK/PD studies in animal models and humans
have shown successful distribution of DPV throughout the lower genital
tract and biologically relevant DPV concentrations in vaginal ﬂuids and
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successful [36](Kenney et al. submitted). Ex vivomacaque explant chal-
lenge models demonstrated the antiviral activity of MIV-150 in tissue
and vaginal ﬂuid from macaques treated with MIV-150-containing
IVRs[34] (Ugaonkar et al., in preparation). Notably, a prototype IVR car-
ryingMZC and LNG (MZCL IVR) was found to signiﬁcantly reduce SHIV-
RT infection and HSV-2 vaginal shedding after repeated SHIV-RT/HSV-2
co-challenge, and deliver target blood levels of LNG. Finally, a recent
report described that a TDF IVR provided full protection of macaques
against repeated SHIV-RT challenge, which was associated with TFV
levels in vaginal ﬂuid and ex vivo antiviral activity of cervicovaginal
lavage samples [37].
6.3. In vivo evaluation of microbicide formulation efﬁcacy
The regulatory agencies still do not require the preclinical testing of
efﬁcacy of microbicide candidates in order to approve them for clinical
trials. This is due to the lack of extensive validation of the animalmodels
that are currently used. However, strong efﬁcacy data from animal stud-
ies may help to select a lead formulation/device, although recognizing
that the relevance of the animal model to the human system needs
further investigation.
6.3.1. Monkey and murine models to test efﬁcacy against HIV
These models in macaques can be performed with a single higher
dose of SHIV typically in DepoProvera-treated animals [17,28,29,36,
38,51,53,58,100–102] or repeated lower doses of SHIV on non-
DepoProvera-treated animals [37,56,103–106] to more closely
mimic the real scenario of human exposure to HIV. Both models
have their advantages and disadvantages. The higher single dose
model animals are pretreated with DepoProvera to thin the vaginal
epithelium and increase susceptibility to SHIV infection while the
product is applied before or after the single challenge. This treatment,
together with the high dose of the virus used, could be too demanding
to screen for potential microbicides. However, if the microbicide blocks
transmission under these conditions, it may be considered a microbi-
cidewith robust activity againstHIV. The secondmodel involves repeat-
edly exposing macaques to lower doses of SHIV with the microbicide
being applied repeatedly at set times relative to each challenge. The
repeated challenge model more readily facilitates the evaluation of
the effectiveness of the candidate microbicide under controlled condi-
tions that are more akin to real life settings, estimates intervention
efﬁcacy, can study natural resistance to infection and also demonstrates
product safety after prolonged use. The disadvantages include a longer
follow up time (a single experiment may take about one year) and
uncertainty regarding point of infection. In general, bothmodels (single
or repeated viral challenges) need further validation and have the
disadvantages of (i) being expensive, (ii) not being able to use cell-
associated virus in the inoculum, and (ii) not simulating the effects of
intercourse on product efﬁcacy.
The chimeric bone marrow–liver–thymus humanized mice model
(BLT mice model) has been also widely used in the microbicide ﬁeld
[107]. In this model, human fetal bone marrow cells, liver and thymus
are transplanted into immunodeﬁcient mouse strains resulting in
long-term systemic repopulation with human T cells, B cells, mono-
cytes/macrophages, andDCs. The activity of 1% TFVgel in an experimen-
tal design mimicking CAPRISA 004, showed a similar level of protection
when compared to the Phase 2b trial results [22]. The disadvantages of
this model include the limited availability of human fetal liver tissues
and the high cost of the surgical procedure to produce the BLT mouse.
Another murine model has been recently described [108], and
explores transmission of chimeric HIV by mating in conventional
mice. The model consists in mating EcoHIV/NDK-infected male mice
with conventional female mice allowing transmission of the virus
during coitus. The EcoHIV/NDK chimeric HIV expresses all HIV structur-
al and regulatory genes but contains a rodent-tropic envelope. Themodel showed prevention of HIV infection if female mice were
pericoitaly treated with NRTIs and also showed reduced susceptibility
to infection during estrus. One disadvantage is that microbicide candi-
dates targeting HIV entry cannot be assayed using this particular
model due to the absence of HIV glycoproteins in the viral envelope.
6.3.2. Murine and monkey models to test efﬁcacy against HSV-2
The vaginal and rectal mouse models to study the efﬁcacy of
microbicides with antiviral activity against HSV-2 are the most widely
used [29,58,60,109–113]. Mice are examined and scored daily for ap-
proximately 20 days, starting on days 3–4 after vaginal or rectal inocu-
lation. Any mice with symptoms of infection including swelling, hair
loss, redness, hind limb paralysis, and/or lesions in the vaginal or rectal
area are scored as infected and euthanized. The model has been used to
challenge mice intravaginally with HSV-2 in the presence of human
seminal plasma and explore the possible interference of this biological
ﬂuid on the anti-herpes activity of potential microbicides [111,114].
Themousemodels have the advantage of low cost and the use of inbred
mouse line but the model lacks spontaneous reactivation of virus as
seen in humans.
In order to test the activity of putative microbicides against both
immunodeﬁciency virus and HSV-2 (infection and shedding), we
established a rhesus macaque co-infection model (single or repeated
exposure) [51,115] (Kenney et al. submitted). Similar to humans, infec-
tion of macaques with HSV-2 resulted in sporadic HSV-2 shedding, de-
tection of genital lesions in ~10% of the animals, and reactivation of
HSV-2 sheddinguponmucosal trauma.Most recently,we demonstrated
that the levels and frequencies of HSV-2 were signiﬁcantly greater in
animals after repeated SHIV-RT/HSV-2 co-challenge compared to
those infected by a single higher dose SHIV-RT/HSV-2 co-challenge
(Kenney et al. submitted). This model allowed us to demonstrate the
ability of MZC-containing IVRs to signiﬁcantly block SHIV-RT infection,
reduce (although not signiﬁcantly) HSV-2 infection, and signiﬁcantly
lower HSV-2 shedding (Kenney et al. submitted). While the HSV-2
dosing still might need optimization (i.e., lowering so as not to over-
power a product, since the inoculum used is still approximately a log
higher than the levels detected in seminal ﬂuids [116–118]), these
data underscore the potential for this sort of model in evaluating
promising microbicide candidates.
Other models include guinea pigs (Cavia porcellus) [119] or cotton
rat (Sigmodon hispidus) [120] that have the advantage to reproduce
the spontaneous reactivation of virus seen in humans.
6.3.3. Murine and monkey models to test efﬁcacy against HPV
Two animalmodels (inmice andmacaques) have been described for
HPV [121,122]. These models involve the use of HPV PsVs, which, as
described before, contain a plasmid with reporter genes within the
viral capsid composed of the L1 and L2 proteins. The HPV PsVs have
the ability to mimic the early steps of infection from viral adsorption
to entry into a basal keratinocyte where the reporter gene (luciferase)
is expressed and quantiﬁed through in vivo imaging techniques. Similar
to what was discussed in the HSV-2 murinemodel, seminal plasma can
be used with the viral inoculum to test any possible detrimental effects
on the potential microbicide [70]. Using these models carrageenan has
been identiﬁed as a promising microbicide candidate to prevent
HPV acquisition [29,70,121,122]. The model is a good tool to test for-
mulations that may block viral adsorption and/or entry but not any
of the subsequent steps in the viral replication cycle. Table 3 summa-
rizes advantages and disadvantages of in vivo assays to measure
safety and efﬁcacy (HIV, HSV-2 and HPV) of potential microbicide
formulations.
7. Core investigational new drug (IND)-enabling studies
Once the lead microbicide formulation is selected, in vivo Good
Laboratory Practices (GLP)-compliant single and repeated dose vaginal
Table 3
Advantages and disadvantages of in vivomodels to test safety and efﬁcacy of potential microbicide formulations.
Advantages Disadvantages
Toxicological studies in mammals • Rabbit vaginal irritation (RVI) model is the most
commonly used.
Most sensitive indicator of irritation/inﬂammation.
• RVI determines epithelial ulceration, leucocyte inﬁltration,
edema and vascular congestion.
• The sheep model allows colposcopy and Optical coherence
tomography (OCT).
• Anatomical and physiological differences with humans.
• Test material enters urethra and bladder in rabbits what
may induce cystitis.
• Potential for exaggerated response to product exposure in
RVI (vs. exposure in humans).
• Labor intensive, costly.
Anti-HIV activity in mice
EcoHIV/NDK chimeric HIV • Reproduces physiological conditions of vaginal intercourse
• As suggested for HIV transmission in humans, HIV
transmission in mice is affected by hormonal environment
• Reproductive tract epithelium and function
(estrous cycle vs. menstrual cycle) are different from humans
• Products targeting HIV envelope cannot be assessed
Humanized mice (BLT) • HIV infects human cells
• Allows testing efﬁcacy against cell-free and
cell-associated virus
• Important for initial screening of safety and
anti-HIV activity of vaginal microbicides
• Reproductive tract epithelium and function
(estrous cycle vs. menstrual cycle) are different from humans
• Mice cannot be bred and must be generated de novo
• Requires artiﬁcially sterile environment
• Dysregulation of innate immune responses
• Labor intensive, costly
Anti-HSV-2 activity in small
animal models
• Fast, robust and inexpensive compared to
other animal models
• Guinea pigs and cotton rats show spontaneous
HSV-2 reactivation
• Effect of seminal plasma on microbicides efﬁcacy
can be explored
• Lack of spontaneous HSV-2 reactivation in mice as seen in humans
• The virus challenge does not simulate effect of intercourse
Anti-SIV/SHIV/HSV-2 activity in NHP • Reproductive mucosa is broadly comparable to humans
• Macaques have similar, but variable, reproductive cycles
compared to humans
• As suggested for HIV transmission, sex hormones are
suggested to inﬂuence vaginal SIV/SHIV transmission
• Single vaginal high cell-free SIV/SHIV dose challenge in
Depo-treated animals
• Repeated more limited dose vaginal challenge on
non-Depo-treated animals
• Single and repeated co-challenge with SHIV
and HSV-2 to assess activity against infection and shedding
• Effect of seminal plasma on microbicides efﬁcacy
can be explored
• Genetic differences between SIV and HIV
• SIV/SHIV vs. HIV disease course
• High challenge dose is stringent
• Immunosuppressive effect of Depo treatment
• Repeated low-dose challenge requires long follow up
• The virus challenge does not simulate effect of intercourse
• Availability issue, cost
• Limited data on SHIV cell-associated challenge
• Lower HSV-2 dose might be more physiological
Anti-HPV activity in mice and macaques • Effect of seminal plasma on microbicides efﬁcacy
can be explored
• Products targeting steps subsequent to viral adsorption/entry
cannot be assessed
• The virus challenge does not simulate effect of intercourse
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approval requires performing toxicological studies in two different ani-
mal species.
Animal models in rabbits, pigs, mice andmonkeys are used to assess
the inﬂammatory and potential irritability of formulations designed for
vaginal use. The rabbit vaginal irritation (RVI) model [123] is perhaps
the most used and the only one the FDA approves for the evaluation
of vaginal irritation. The model involves the repeated application of a
formulation in the vagina of rabbits and monitors the presence of ery-
thema, edema, and vaginal secretions. The study also includes obtaining
histological sections of tissues exposed to the formulation to assess the
presence of epithelial exfoliation, leukocyte inﬁltration, vascular con-
gestion and edema.
The female rabbit reproductive system has several anatomical/
histological characteristics that are particularly different from humans.
Rabbits have cuboidal/columnar tissue in anterior to mid vaginal epi-
thelia and stratiﬁed squamous in the posterior vaginal, persistent estrus
and a vaginal pH between 7.0–8.0. Guinea pigs and rats can be more
similar to humans in these terms but RVI is a more sensitive indicator
of vaginal irritation. An alternative to the RVI model is the enhanced
RVI model that in addition to the outcomes mentioned above looks at
immunotoxicity [124].
The RVI or enhanced RVI models are probably the primary assays
when testing gel formulations but in the case of IVR a better approach
may be the sheep vaginal irritation model [125]. The sheep model
may include pre- and post-treatment colposcopy and optical coherencetomography (OCT) images that are graded based on an objective
scoring system. Biopsies are also collected to investigate the degree of
epithelial injury through histology and OCT. However, in order to get
data in two different animal species, segments of the IVR can be also
tested intravaginally in rabbits [126].
As mentioned earlier, the vaginal irritation/toxicity studies with
toxicokinetics must be performed in two different animal species.
This may include acute rabbit and rat models in which a single
dose of different formulations containing increasing amounts of the
APIs is administered. If the single dose study does not reveal any
safety concerns, then vaginal chronic (14-day through 90-day) tox-
icity and PK studies with toxicokinetics in two animal species are
performed. The duration of chronic studies is determined by the du-
ration of studies to be conducted in humans during the clinical trials.
For example if a 14 day daily application is proposed in human studies, a
similar number of days should be tested in the animal models to access
vaginal irritation/toxicity.
The vaginal irritation/toxicity assays mentioned above are the key
GLP-compliant tests of an optimized microbicide formulation for a suc-
cessful IND application. However, when looking at a new API with no
human experience or at other classes of APIs, for example proteins, an
additional set of GLP toxicological testing in animals may be needed/
recommended by the regulatory agency. Thesemay include intravenous
single dose studies, subacute immunogenicity testing, sensitization
study, cardiovascular telemetry study and central nervous system safety
[63].
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The overarching goal of preclinical safety and efﬁcacy testing is to in-
form selection of formulations for Phase 1 testing by identifying micro-
bicide candidates with the best risk/beneﬁt ratios. Preclinical safety and
efﬁcacy testing of microbicide candidates involves a large number of
in vitro, ex vivo, and in vivo assays and models. Some are dictated by
the regulatory agencies; others are not. In many cases the assays and
models are not harmonized, which makes it difﬁcult to objectively
compare data on candidates from different microbicide developers.
Pre-IND meetings with the US FDA, for example, can be used to get
early feedback on the suitability of a preclinical testing plan.Acknowledgments
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